Patent US3957995A successfully refreshed from Google Patents.
← Back to Patent Explorer
US3957995A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical composition comprising vincamine and theophylline

Assignee: Parcor SARL
•
Filing: 1974-12-23
•
Granted: 1976-05-18
•
Expires: 1994-12-23
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The herein disclosed invention is directed to pharmaceutical compositions of vincamine and theophylline having cerebral vasodilator activity.

Inventors

  • 👤 Armand Amselem

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 17:09
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 29 words
A pharmaceutical composition comprising 0.005 to 0.50 grams of vincamine and 0.050 to 0.500 grams of theophylline, the weight ratio of vincamine to theophylline being from 0.01 to 0.1:1.
Claim 2
Dependent Claim 29 words
A pharmaceutical composition comprising 0.005 to 0.50 grams of vincamine and 0.050 to 0.500 grams of theophylline, the weight ratio of vincamine to theophylline being from 0.01 to 0.1:1.
Claim 3
Dependent Claim 15 words
Composition as claimed in claim 1, wherein said weight ratio is from 0.025 to 0.075:1.
Claim 4
Dependent Claim 32 words
Composition as claimed in claim 1, wherein vincamine is present as a derivative thereof selected from the group consisting of a non-toxic addition salt thereof and a non-toxic quaternary ammonium derivative thereof.
Claim 5
Dependent Claim 28 words
Composition as claimed in claim 1, wherein theophylline is present as a derivative thereof selected from the group consisting of theophylline ethylenediamine, dihydroxypropyl theophylline and diethylene-diamine theophylline ethanoate.
Claim 6
Dependent Claim 32 words
Composition as claimed in claim 2, wherein vincamine is present as a derivative thereof selected from the group consisting of a non-toxic addition salt thereof and a non-toxic quaternary ammonium derivative thereof.
Claim 7
Dependent Claim 25 words
Composition as claimed in claim 3, wherein theophylline is present as a derivative thereof selected from the group consisting of theophylline and diethylene-diamine theophylline ethanoate.
Claim 8
Dependent Claim 25 words
Composition as claimed in claim 1, which comprises 0.010 to 0.100 grams of phenobarbital, the weight ratio of phenobarbital to theophylline being 2 to 0.02:1.
Claim 9
Dependent Claim 17 words
Composition as claimed in claim 7, wherein said weight ratio of the phenobarbital to theophylline is 0.1:1.
Claim 10
Dependent Claim 11 words
Composition as claimed in claim 1 in the form of tablets.
Claim 11
Dependent Claim 11 words
Composition as claimed in claim 1 in the form of capsules.
Claim 12
Dependent Claim 11 words
Composition as claimed in claim 1 in the form of suppository.
Claim 13
Dependent Claim 45 words
A process for treating a patient who suffers from cerebral circulatory deficiency, which comprises administering daily to said patient from 0.005 to 0.100 g vincamine together with from 0.05 to 1.50 g theophylline, the weight ratio of vincamine to theophylline being from 0.01 to 0.1:1.
Claim 14
Dependent Claim 45 words
A process for treating a patient who suffers from cerebral circulatory deficiency, which comprises administering daily to said patient from 0.005 to 0.100 g vincamine together with from 0.05 to 1.50 g theophylline, the weight ratio of vincamine to theophylline being from 0.01 to 0.1:1.
Claim 15
Dependent Claim 37 words
A process as claimed in claim 12, which comprises administering daily to said patient from 0.010 to 0.300 g phenobarbital together with said vincamine and theophylline, the weight ratio of phenobarbital to theophylline being 2 to 0.02:1.
Claim 16
Dependent Claim 40 words
Process as claimed in claim 13, which comprises administering said vincamine, theophylline and phenobarbital as dosage unit forms, each form comprising from 0.005 to 0.050 g vincamine, from 0.050 to 0.500 g theophylline and from 0.010 to 0.100 g phenobarbital.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1979-05-18 1979-11-17 1980-05-18 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1983-05-18 1983-11-17 1984-05-18 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1987-05-18 1987-11-17 1988-05-18 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag